![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: APCDD1L |
Gene summary for APCDD1L |
![]() |
Gene information | Species | Human | Gene symbol | APCDD1L | Gene ID | 164284 |
Gene name | APC down-regulated 1 like | |
Gene Alias | APCDD1L | |
Cytomap | 20q13.32 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | B4DDQ9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
164284 | APCDD1L | ATC09 | Human | Thyroid | ATC | 1.72e-39 | 1.23e+00 | 0.2871 |
164284 | APCDD1L | ATC12 | Human | Thyroid | ATC | 7.11e-83 | 1.92e+00 | 0.34 |
164284 | APCDD1L | ATC13 | Human | Thyroid | ATC | 1.09e-02 | 1.14e-01 | 0.34 |
164284 | APCDD1L | ATC1 | Human | Thyroid | ATC | 2.50e-37 | 1.31e+00 | 0.2878 |
164284 | APCDD1L | ATC4 | Human | Thyroid | ATC | 2.01e-98 | 2.18e+00 | 0.34 |
164284 | APCDD1L | ATC5 | Human | Thyroid | ATC | 2.43e-03 | 1.23e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001605525 | Thyroid | ATC | Wnt signaling pathway | 234/6293 | 444/18723 | 4.64e-17 | 4.31e-15 | 234 |
GO:019873825 | Thyroid | ATC | cell-cell signaling by wnt | 234/6293 | 446/18723 | 9.26e-17 | 8.25e-15 | 234 |
GO:003011125 | Thyroid | ATC | regulation of Wnt signaling pathway | 177/6293 | 328/18723 | 1.83e-14 | 1.05e-12 | 177 |
GO:003017815 | Thyroid | ATC | negative regulation of Wnt signaling pathway | 85/6293 | 170/18723 | 6.94e-06 | 7.16e-05 | 85 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APCDD1L | SNV | Missense_Mutation | c.1193N>A | p.Gly398Asp | p.G398D | Q8NCL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
APCDD1L | SNV | Missense_Mutation | rs778135452 | c.1331N>A | p.Arg444His | p.R444H | Q8NCL9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
APCDD1L | deletion | In_Frame_Del | novel | c.837_848delCCTGGGCGGCTG | p.His279_Trp283delinsGln | p.H279_W283delinsQ | Q8NCL9 | protein_coding | TCGA-S3-A6ZG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | ||
APCDD1L | SNV | Missense_Mutation | c.860N>G | p.Ser287Trp | p.S287W | Q8NCL9 | protein_coding | deleterious(0.03) | possibly_damaging(0.666) | TCGA-R2-A69V-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
APCDD1L | SNV | Missense_Mutation | c.954N>A | p.Phe318Leu | p.F318L | Q8NCL9 | protein_coding | deleterious(0) | benign(0.337) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
APCDD1L | SNV | Missense_Mutation | c.65N>T | p.Ala22Val | p.A22V | Q8NCL9 | protein_coding | tolerated(0.26) | benign(0.001) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
APCDD1L | SNV | Missense_Mutation | rs147147447 | c.94C>T | p.Arg32Cys | p.R32C | Q8NCL9 | protein_coding | deleterious(0.03) | possibly_damaging(0.528) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APCDD1L | SNV | Missense_Mutation | c.1315N>A | p.Asp439Asn | p.D439N | Q8NCL9 | protein_coding | tolerated(0.08) | benign(0.243) | TCGA-AA-3986-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
APCDD1L | SNV | Missense_Mutation | rs761827739 | c.1036N>T | p.Arg346Cys | p.R346C | Q8NCL9 | protein_coding | deleterious(0.03) | possibly_damaging(0.731) | TCGA-AA-3994-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
APCDD1L | SNV | Missense_Mutation | c.1048G>A | p.Glu350Lys | p.E350K | Q8NCL9 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |